Amicus Therapeutics Inc.

NASDAQ: FOLD · Real-Time Price · USD
7.33
0.21 (2.95%)
At close: Aug 15, 2025, 1:13 PM

Amicus Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
528.29M 399.36M 329.23M 305.51M
Cost of Revenue
52.94M 37.33M 38.6M 34.47M
Gross Profit
475.35M 362.03M 290.63M 271.05M
Operating Income
24.88M -73.49M -204.43M -199.92M
Interest Income
5.41M 7.08M 3.02M 509K
Pretax Income
-28.76M -150.1M -242.04M -241.55M
Net Income
-56.11M -151.58M -236.57M -250.46M
Selling & General & Admin
323.38M 275.27M 213.04M 192.71M
Research & Development
109.36M 152.38M 276.68M 272.05M
Other Expenses
17.73M n/a 5.34M 6.21M
Operating Expenses
432.74M 427.65M 495.06M 470.97M
Interest Expense
49.6M 50.15M 37.12M 32.47M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
503.42M 472.85M 533.66M 505.43M
Income Tax Expense
27.35M 1.48M -5.47M 8.91M
Shares Outstanding (Basic)
304.38M 295.16M 289.06M 271.42M
Shares Outstanding (Diluted)
304.38M 295.16M 289.06M 271.42M
EPS (Basic)
-0.18 -0.51 -0.82 -0.92
EPS (Diluted)
-0.18 -0.51 -0.82 -0.92
EBITDA
29.39M -92.08M -199.58M -202.87M
EBIT
20.84M -99.95M -204.92M -209.08M
Depreciation & Amortization
8.55M 7.87M 5.34M 6.21M